logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Androgen class drugs

    FiltersReset Filters
    4 results

    • androgel

      (Testosterone)
      ASCEND Therapeutics U.S., LLC
      Usage: AndroGel 1.62% is indicated for testosterone replacement therapy in adult males with primary or hypogonadotropic hypogonadism due to various conditions. Its safety and efficacy in age-related hypogonadism and in males under 18 have not been established.

    • aveed

      (testosterone undecanoate)
      ENDO USA, Inc.
      Usage: AVEED is indicated for testosterone replacement therapy in adult males with conditions related to testosterone deficiency, including primary and hypogonadotropic hypogonadism. It should only be used when benefits outweigh risks, with safety and efficacy not established for age-related hypogonadism or in males under 18.

    • jatenzo

      (testosterone undecanoate)
      TOLMAR Inc.
      Usage: JATENZO (testosterone undecanoate) is indicated for testosterone replacement therapy in adult males with conditions leading to low testosterone, including primary and hypogonadotropic hypogonadism. It is not established for safety and efficacy in males under 18 years old.

    • natesto

      (testosterone)
      Acerus Pharmaceuticals Corporation
      Usage: Natesto is indicated for testosterone replacement therapy in adult males with primary or hypogonadotropic hypogonadism due to various causes, such as testicular failure or pituitary-hypothalamic injury. Its safety and efficacy in age-related hypogonadism and in males under 18 years have not been established.